J. Jefferson Smith Sells 10,200 Shares of Precision BioSciences (NASDAQ:DTIL) Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) insider J. Jefferson Smith sold 10,200 shares of the business’s stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $4.03, for a total transaction of $41,106.00. Following the completion of the sale, the insider directly owned 110,184 shares in the company, valued at approximately $444,041.52. This trade represents a 8.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Precision BioSciences Price Performance

DTIL stock opened at $4.20 on Friday. The firm has a market capitalization of $55.69 million, a P/E ratio of -0.50 and a beta of 1.20. The company has a current ratio of 3.45, a quick ratio of 3.45 and a debt-to-equity ratio of 1.35. The firm has a 50 day moving average of $4.55 and a 200-day moving average of $5.12. Precision BioSciences, Inc. has a 12 month low of $3.75 and a 12 month high of $8.82.

Precision BioSciences (NASDAQ:DTIL) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($1.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($1.53). Precision BioSciences had a negative return on equity of 233.77% and a negative net margin of 11,977.36%.The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $5.40 million. During the same quarter in the previous year, the firm posted ($2.25) earnings per share. As a group, sell-side analysts predict that Precision BioSciences, Inc. will post -1.23 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Precision BioSciences in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $60.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its holdings in Precision BioSciences by 5.5% in the 2nd quarter. Geode Capital Management LLC now owns 77,712 shares of the company’s stock valued at $326,000 after purchasing an additional 4,025 shares during the last quarter. Lynx1 Capital Management LP boosted its position in shares of Precision BioSciences by 0.6% during the 3rd quarter. Lynx1 Capital Management LP now owns 1,042,596 shares of the company’s stock worth $5,755,000 after acquiring an additional 6,545 shares in the last quarter. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Precision BioSciences during the 3rd quarter worth about $72,000. Virtu Financial LLC purchased a new stake in Precision BioSciences during the third quarter worth approximately $84,000. Finally, GSA Capital Partners LLP acquired a new position in Precision BioSciences in the third quarter valued at approximately $98,000. Hedge funds and other institutional investors own 37.99% of the company’s stock.

Precision BioSciences Company Profile

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.